CSBR
CHAMPIONS ONCOLOGY, INC.
NASDAQ · Healthcare · Biotechnology · US
$5.15
+1.28%Year over year
Reported trailing growth
- Revenue
- +6.7%
- EBITDA
- -89.8%
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -17.2%
- EBITDA
- +552.8%
- EPS
- +239.2%
Three-year CAGR
- Revenue
- +3.3%
- EBITDA
- -92.9%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026